What is new in the 2018 Chinese hypertension guideline and the implication for the management of hypertension in Asia?
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Wang, Ji-Guang | - |
dc.contributor.author | Chia, Yook-Chin | - |
dc.contributor.author | Chen, Chen-Huan | - |
dc.contributor.author | Park, Sungha | - |
dc.contributor.author | Hoshide, Satoshi | - |
dc.contributor.author | Tomitani, Naoko | - |
dc.contributor.author | Kabutoya, Tomoyuki | - |
dc.contributor.author | Shin, Jinho | - |
dc.contributor.author | Turana, Yuda | - |
dc.contributor.author | Soenarta, Arieska Ann | - |
dc.contributor.author | Tay, Jam Chin | - |
dc.contributor.author | Buranakitjaroen, Peera | - |
dc.contributor.author | Nailes, Jennifer | - |
dc.contributor.author | Huynh Van Minh | - |
dc.contributor.author | Siddique, Saulat | - |
dc.contributor.author | Sison, Jorge | - |
dc.contributor.author | Sogunuru, Guru Prasad | - |
dc.contributor.author | Sukonthasarn, Apichard | - |
dc.contributor.author | Teo, Boon Wee | - |
dc.contributor.author | Verma, Narsingh | - |
dc.contributor.author | Zhang, Yu-Qing | - |
dc.contributor.author | Wang, Tzung-Dau | - |
dc.contributor.author | Kario, Kazuomi | - |
dc.date.accessioned | 2021-08-02T09:51:25Z | - |
dc.date.available | 2021-08-02T09:51:25Z | - |
dc.date.created | 2021-05-12 | - |
dc.date.issued | 2020-03 | - |
dc.identifier.issn | 1524-6175 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/10581 | - |
dc.description.abstract | The new Chinese hypertension guideline comprehensively covers almost all major aspects in the management of hypertension. In this new guideline, hypertension remains defined as a systolic/diastolic blood pressure of at least 140/90 mm Hg. For risk assessment, a qualitative approach is used similarly as in previous Chinese guidelines according to the blood pressure level and the presence or absence of other risk factors, target organ damage, cardiovascular complications, and comorbid diseases. The therapeutic target is 140/90 mm Hg in general, and if tolerated, especially in high-risk patients, can be more stringent, that is, 130/80 mm Hg. However, a less stringent target, that is, 150/90 mm Hg, is used in the younger (65-79 years, if tolerated, 140/90 mm Hg) and older elderly (>= 80 years). Five classes of antihypertensive drugs, including beta-blockers, can be used either in initial monotherapy or combination. The guideline also provided information on the management of hypertension in several special groups of patients and in the presence of secondary causes of hypertension. To implement the guideline recommendations, several nationwide hypertension control initiatives are being undertaken with new technology. The new technological platforms hopefully will help improve the management of hypertension and generate scientific evidence for future hypertension guidelines, including a possible Asian hypertension guideline in the near future. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | WILEY | - |
dc.title | What is new in the 2018 Chinese hypertension guideline and the implication for the management of hypertension in Asia? | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Shin, Jinho | - |
dc.identifier.doi | 10.1111/jch.13803 | - |
dc.identifier.scopusid | 2-s2.0-85078722210 | - |
dc.identifier.wosid | 000508063300001 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CLINICAL HYPERTENSION, v.22, no.3, pp.363 - 368 | - |
dc.relation.isPartOf | JOURNAL OF CLINICAL HYPERTENSION | - |
dc.citation.title | JOURNAL OF CLINICAL HYPERTENSION | - |
dc.citation.volume | 22 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 363 | - |
dc.citation.endPage | 368 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
dc.relation.journalWebOfScienceCategory | Peripheral Vascular Disease | - |
dc.subject.keywordPlus | RISK | - |
dc.subject.keywordPlus | POPULATION | - |
dc.subject.keywordPlus | STATEMENT | - |
dc.subject.keywordPlus | DRUGS | - |
dc.subject.keywordPlus | FEVER | - |
dc.subject.keywordAuthor | China | - |
dc.subject.keywordAuthor | guideline | - |
dc.subject.keywordAuthor | hypertension | - |
dc.subject.keywordAuthor | management | - |
dc.identifier.url | https://onlinelibrary.wiley.com/doi/10.1111/jch.13803 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.